MX2021003527A - Tratamiento de baja intensidad de trastornos hematologicos. - Google Patents
Tratamiento de baja intensidad de trastornos hematologicos.Info
- Publication number
- MX2021003527A MX2021003527A MX2021003527A MX2021003527A MX2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A
- Authority
- MX
- Mexico
- Prior art keywords
- low
- hematological disorders
- intensity treatment
- treatment
- intensity
- Prior art date
Links
- 208000014951 hematologic disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000011368 intensive chemotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736393P | 2018-09-25 | 2018-09-25 | |
| US201862772372P | 2018-11-28 | 2018-11-28 | |
| PCT/US2019/052952 WO2020068979A1 (en) | 2018-09-25 | 2019-09-25 | Low-intensity treatment of hematological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003527A true MX2021003527A (es) | 2021-05-27 |
Family
ID=69950910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003527A MX2021003527A (es) | 2018-09-25 | 2019-09-25 | Tratamiento de baja intensidad de trastornos hematologicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240252522A1 (https=) |
| EP (1) | EP3856198A4 (https=) |
| JP (1) | JP2022502498A (https=) |
| KR (1) | KR20210065962A (https=) |
| CN (1) | CN113164502A (https=) |
| AU (1) | AU2019350759A1 (https=) |
| BR (1) | BR112021005539A2 (https=) |
| CA (1) | CA3114002A1 (https=) |
| IL (1) | IL281729A (https=) |
| MX (1) | MX2021003527A (https=) |
| WO (1) | WO2020068979A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| EP3856198A4 (en) * | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| EP4333822A1 (en) | 2021-05-03 | 2024-03-13 | Lead Discovery Center GmbH | Composition comprising an inhibitor of mitochondrial transcription |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
| WO2005102359A1 (en) | 2004-04-22 | 2005-11-03 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| EP4046640A1 (en) * | 2007-02-16 | 2022-08-24 | Rotalec IP Holdings LLC | Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders |
| EP3572071A1 (en) | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| BR112019001570A2 (pt) * | 2016-07-28 | 2019-07-09 | Novartis Ag | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 |
| WO2018101214A1 (ja) | 2016-12-01 | 2018-06-07 | Ｊｘｔｇエネルギー株式会社 | 全芳香族液晶ポリエステル樹脂 |
| EP3856198A4 (en) * | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11980636B2 (en) * | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
-
2019
- 2019-09-25 EP EP19864378.5A patent/EP3856198A4/en active Pending
- 2019-09-25 CN CN201980063289.2A patent/CN113164502A/zh not_active Withdrawn
- 2019-09-25 WO PCT/US2019/052952 patent/WO2020068979A1/en not_active Ceased
- 2019-09-25 BR BR112021005539-8A patent/BR112021005539A2/pt not_active Application Discontinuation
- 2019-09-25 AU AU2019350759A patent/AU2019350759A1/en not_active Abandoned
- 2019-09-25 MX MX2021003527A patent/MX2021003527A/es unknown
- 2019-09-25 JP JP2021540394A patent/JP2022502498A/ja active Pending
- 2019-09-25 US US17/279,556 patent/US20240252522A1/en not_active Abandoned
- 2019-09-25 CA CA3114002A patent/CA3114002A1/en active Pending
- 2019-09-25 KR KR1020217011132A patent/KR20210065962A/ko not_active Ceased
-
2021
- 2021-03-22 IL IL281729A patent/IL281729A/en unknown
- 2021-06-03 US US17/338,561 patent/US12370207B2/en active Active
-
2025
- 2025-06-24 US US19/247,599 patent/US20260014183A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210393665A1 (en) | 2021-12-23 |
| US20240252522A1 (en) | 2024-08-01 |
| EP3856198A1 (en) | 2021-08-04 |
| BR112021005539A2 (pt) | 2021-06-29 |
| CN113164502A (zh) | 2021-07-23 |
| KR20210065962A (ko) | 2021-06-04 |
| EP3856198A4 (en) | 2022-06-22 |
| CA3114002A1 (en) | 2020-04-02 |
| US12370207B2 (en) | 2025-07-29 |
| JP2022502498A (ja) | 2022-01-11 |
| AU2019350759A1 (en) | 2021-04-22 |
| IL281729A (en) | 2021-05-31 |
| US20260014183A1 (en) | 2026-01-15 |
| WO2020068979A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552538A1 (en) | Heavy chain antibodies binding to psma | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| PH12021553145A1 (en) | Multispecific heavy chain antibodies binding to cd22 and cd3 | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| MX2021003527A (es) | Tratamiento de baja intensidad de trastornos hematologicos. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX389242B (es) | Compuestos para su uso en el tratamiento de trastornos neuromusculares | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| TW201613616A (en) | Methods of treating transthyretin (TTR) mediated amyloidosis | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX2020006654A (es) | Métodos intraductales de tratamiento de trastornos de mama. | |
| CR20220656A (es) | Unión de anticuerpos multiespecíficos a bcma | |
| BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
| PH12020551071A1 (en) | Compositions and methods for treating retinal disorders | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| WO2019143883A3 (en) | Compositions and methods for the treatment of cancer | |
| PH12022551371A1 (en) | Macrocycles for use in treating disease | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| MX2019005818A (es) | Preparacion cosmetica de viscosidad mejorada para tratamiento de fibras queratinicas, metodo para incrementar la viscosidad de una preparacion cosmetica, uso de ingredientes modificadores de la viscosidad y metodo de tratamiento de fibras queratinicas. |